Impact of hidradenitis suppurativa on work productivity and associated risk factors

Straalen, Kelsey R. van; Prens, Lisette M.; Hylkema, Tjerk H; Janse, Ineke C.; Dickinson, J. C.; Houwing, Ronald H; Zee, Hessel H. van der; Brouwer, Sandra; Prens, Errol P.; Hórvath, Barbara

doi:10.1016/j.jaad.2020.07.115

Cited by 16 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unemployed patients had higher activity impairment compared with employed patients (mean rank: 61.0 vs. 42.6, p = 0.001) [ 66 ]. In another study, the DLQI, EuroQol-5 Dimensions scores and pain were significantly associated with presenteeism and at-work productivity loss [ 67 ]. Results from the Global Survey of Impact and Healthcare Needs (VOICE) project showed that 14.5% of HS patients were disabled due to their disease [ 68 ].…”

Section: Resultsmentioning

confidence: 99%

“…Several studies have demonstrated a positive correlation between DLQI scores and HS severity (Hurley stages and modified Hurley stages) [ 65 , 69 , 70 , 71 ]. Many HS patients in these studies were unemployed and of those who had a job, many reported problems with presenteeism and overall work impairment that increased along with HS severity [ 64 , 65 , 66 , 67 , 68 , 69 ]. Several recent studies have shown significant HRQoL improvement in patients treated with adalimumab [ 40 , 41 , 42 , 43 , 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of Life in Hidradenitis Suppurativa: An Update

Chernyshov

Finlay

Tómas-Aragonés

et al. 2021

IJERPH

View full text Add to dashboard Cite

Knowledge on hidradenitis suppurativa/acne inversa (HS) is rapidly increasing. HS has a profound impact on patients and their family life. Several factors, such as comorbidities, unemployment and HS severity, make this impact even more severe. The most widely used instrument to measure this impact is the dermatology-specific DLQI. We also identified six HS-specific health-related quality of life (HRQoL) instruments. Of them, HIDRAdisk, HSIA, HiSQOL and HSQoL-24 are better validated but there is still lack of experience of its use. Several treatment methods showed positive effect on patients’ HRQoL. Surgery remains a method with a substantial positive effect on HRQoL. Several studies confirming a positive effect of adalimumab on the HRQoL of patients with HS were published during the last three years. Data on the influence of several other biologics on HRQoL of HS patients are controversial or based on studies with a small number of patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Quality of Life in Hidradenitis Suppurativa: An Update

Chernyshov

Finlay

Tómas-Aragonés

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Our HADS scores at baseline for both depression and anxiety are comparable with those from other observational studies on HS patients. 21,28,49,54,59 As suggested by Patel et al, 15 HS patients may benefit from a multidisciplinary approach to treatment, including for the management of psychological comorbidities.…”

Section: Discussionmentioning

confidence: 99%

“…For women, the main factors associated with a higher frequency of sexual dysfunction were related to disease activity, symptoms, and having a partner, while for men, a higher ED was mainly related to mood disorders such as depression and anxiety. 42 HS also affects work productivity and impairs activity, [48][49][50][51] which was correlated to a decrease in patients' quality of life. On average in a multicenter study including 200 adults with HS, 26 days were missed from work annually due to absenteeism while 63 days were associated with reduced productivity due to HS (presenteeism).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab

et al. 2022

View full text Add to dashboard Cite

Background Real-world knowledge of the burden of hidradenitis suppurativa (HS) on patients remains limited. Objectives To measure the impact of adalimumab on moderate-to-severe HS patients’ health-related quality of life (HRQoL) and work productivity. Methods In 23 Canadian centres, 138 adults with moderate-to-severe HS requiring a change in ongoing therapy were treated with adalimumab for up to 52 weeks as per the physician’s practice. Patient-reported outcome measures (PROMs) were obtained at baseline, weeks 24 and 52 to measure overall HRQoL, HS severity, levels of anxiety and depression, impact and symptoms of HS, work productivity and activity impairment. A post-hoc analysis further explored the PROMs by abscess and inflammatory nodule (AN) count at baseline (≤5, low; 6–10, medium; ≥11, high). Results From baseline to weeks 24 and 52, all PRO overall scores improved significantly ( P ≤ .0023). The number of patients reporting “good disease control” and “complete disease control” increased from 9.7% to 66.4% over 52 weeks. The score in Health Utility Index Mark 3 (HUI3) pain attribute meaningfully decreased over 52 weeks (mean difference ≥.05). The HS symptoms skin “tenderness” and “itchiness” improved the most. Work productivity loss and activity impairment improved by approximately 20% over 52 weeks. Disease burden improved more in 24 week responders with low and medium AN counts at baseline than in those with high AN count or in 24 week nonresponders. Conclusion At week 24 and maintained at week 52 in a real-world setting, adalimumab meaningfully improved HRQoL, work productivity, and activity impairment in moderate-to-severe HS patients.

show abstract